Grafa News and Videos — Page 932

IDEAYA Biosciences (NASDAQ:IDYA) marked a milestone first quarter in 2026, transitioning into a late-stage regulatory company following a decisive clinical win in its lead oncology program and the initiation of a rolling New Drug Application (NDA).

Integra LifeSciences (NASDAQ:IART) signaled a turning point in its operational recovery today, raising its full-year profit guidance even as it recorded a GAAP loss during a quarter defined by significant leadership changes and supply chain stabilization.

Enlight Renewable Energy 9NASDAQ:ENLT) delivered a high-growth first quarter, reporting a 54% increase in total revenues and income as the company aggressively scales its combined solar and storage portfolio across the United States, Europe, and the Middle East.

KBR (NYSE:KBR) reported a resilient start to fiscal 2026, leveraging a record-high backlog to navigate a temporary decline in revenue as large-scale contingency work in Europe begins to wind down.

Pediatrix Medical Group (NYSE:MD) reported first-quarter earnings that beat Wall Street estimates on both the top and bottom lines, as favorable reimbursement shifts helped the physician services leader overcome a softer volume environment.

Fortrea (NASDAQ:FTRE) reported a steady start to 2026, characterized by robust new business wins and a growing backlog that provides a solid foundation for the company as it navigates its second full year as a standalone clinical research organization (CRO).

Henry Schein (NASDAQ:HSIC) delivered a solid start to 2026, reporting a 6.3% increase in total net sales as the company’s core dental business benefited from resilient patient volumes and a strategic push into the value implant market.

Archer-Daniels-Midland (NYSE:ADM) delivered a major upgrade to its full-year 2026 profit outlook, betting on a resurgence in the U.S. biofuels market to offset a first quarter tempered by volatile commodity pricing and mark-to-market accounting.

Revvity (NYSE:RVTY) exceeded Wall Street estimates for the first quarter and unveiled a major strategic pivot, announcing its intention to divest its China Immunodiagnostics business to sharpen its focus on high-growth life sciences and specialty diagnostics.

Willis Lease Finance (NASDAQ:WLFC) delivered record-breaking results for the first quarter of 2026, capitalizing on a persistent global shortage of commercial aircraft engines that pushed lease yields and service demand to all-time highs.